NCT03167476 is a clinical trial in Lymphoma, sponsored by University of Electronic Science and Technology of China.

Who is sponsoring NCT03167476?

NCT03167476 is sponsored by University of Electronic Science and Technology of China.

What condition does NCT03167476 study?

NCT03167476 studies Lymphoma, Hyperplasia Lymphoid Reactive.

Is NCT03167476 still recruiting?

NCT03167476 is currently status unknown. Last updated 30 May 2017.

Last reviewed 2017-05-30 · How we verify

NCT03167476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma

Status unknown Last updated 30 May 2017

What this trial tests

trial in Lymphoma in 200 participants. Status unknown.

Timeline

1 August 2016

Primary endpoint
1 December 2017

1 December 2018

Quick facts

Lead sponsor	University of Electronic Science and Technology of China
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 August 2016
Primary completion	1 December 2017
Estimated completion	1 December 2018
Sites	1 location across China

Conditions studied

Lymphoma — all drugs for Lymphoma →
Hyperplasia Lymphoid Reactive — all drugs for Hyperplasia Lymphoid Reactive →

Sponsor

University of Electronic Science and Technology of China

Who can join

18 and older, any sex, with Lymphoma or Hyperplasia Lymphoid Reactive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives are to: 1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma. 2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects. 3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia. The objectives are to: 1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma. 2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects. 3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia. This trial involves tissue samples diagnosed as lymphoma and reactive hyperplasia. The investigators will develop panels of miRNAs that are specific biomarkers of lymphoma, and assist clinical outcomes with these miRNAs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other University of Electronic Science and Technology of China trials

Trials by the same sponsor.

NCT07416370 — Neurofeedback Training of Anterior Insula Activity Based on Unidimensional vs. Multidimensional Interoceptive Regulation · NA · enrolling by invitation
NCT07389486 — Continuous vs. Intermittent Rt-fMRI Neurofeedback Training of the Anterior Insula · NA · recruiting
NCT07425938 — Oxytocin's Effects on Emotional Processing and Its Acting Routes · NA · recruiting
NCT07364084 — Real-time Neurofeedback Training of the Medial Prefrontal Cortex Based on Imagined Social Support · NA · recruiting
NCT07367672 — The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03167476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Electronic Science and Technology of China
Last refreshed: 30 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03167476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing